Cargando…
No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
Gliflozins are inhibitors of the renal proximal tubular sodium-glucose co-transporter-2 (SGLT-2), that inhibit reabsorption of urinary glucose and they are able to reduce hyperglycemia in patients with type 2 diabetes. A renoprotective function of gliflozins has been proven in diabetic nephropathy,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013746/ https://www.ncbi.nlm.nih.gov/pubmed/31936266 http://dx.doi.org/10.3390/ijms21020391 |
_version_ | 1783496474910261248 |
---|---|
author | Baer, Patrick C. Koch, Benjamin Freitag, Janina Schubert, Ralf Geiger, Helmut |
author_facet | Baer, Patrick C. Koch, Benjamin Freitag, Janina Schubert, Ralf Geiger, Helmut |
author_sort | Baer, Patrick C. |
collection | PubMed |
description | Gliflozins are inhibitors of the renal proximal tubular sodium-glucose co-transporter-2 (SGLT-2), that inhibit reabsorption of urinary glucose and they are able to reduce hyperglycemia in patients with type 2 diabetes. A renoprotective function of gliflozins has been proven in diabetic nephropathy, but harmful side effects on the kidney have also been described. In the current project, primary highly purified human renal proximal tubular epithelial cells (PTCs) have been shown to express functional SGLT-2, and were used as an in vitro model to study possible cellular damage induced by two therapeutically used gliflozins: empagliflozin and dapagliflozin. Cell viability, proliferation, and cytotoxicity assays revealed that neither empagliflozin nor dapagliflozin induce effects in PTCs cultured in a hyperglycemic environment, or in co-medication with ramipril or hydro-chloro-thiazide. Oxidative stress was significantly lowered by dapagliflozin but not by empagliflozin. No effect of either inhibitor could be detected on mRNA and protein expression of the pro-inflammatory cytokine interleukin-6 and the renal injury markers KIM-1 and NGAL. In conclusion, empa- and dapagliflozin in therapeutic concentrations were shown to induce no direct cell injury in cultured primary renal PTCs in hyperglycemic conditions. |
format | Online Article Text |
id | pubmed-7013746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70137462020-03-09 No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro Baer, Patrick C. Koch, Benjamin Freitag, Janina Schubert, Ralf Geiger, Helmut Int J Mol Sci Article Gliflozins are inhibitors of the renal proximal tubular sodium-glucose co-transporter-2 (SGLT-2), that inhibit reabsorption of urinary glucose and they are able to reduce hyperglycemia in patients with type 2 diabetes. A renoprotective function of gliflozins has been proven in diabetic nephropathy, but harmful side effects on the kidney have also been described. In the current project, primary highly purified human renal proximal tubular epithelial cells (PTCs) have been shown to express functional SGLT-2, and were used as an in vitro model to study possible cellular damage induced by two therapeutically used gliflozins: empagliflozin and dapagliflozin. Cell viability, proliferation, and cytotoxicity assays revealed that neither empagliflozin nor dapagliflozin induce effects in PTCs cultured in a hyperglycemic environment, or in co-medication with ramipril or hydro-chloro-thiazide. Oxidative stress was significantly lowered by dapagliflozin but not by empagliflozin. No effect of either inhibitor could be detected on mRNA and protein expression of the pro-inflammatory cytokine interleukin-6 and the renal injury markers KIM-1 and NGAL. In conclusion, empa- and dapagliflozin in therapeutic concentrations were shown to induce no direct cell injury in cultured primary renal PTCs in hyperglycemic conditions. MDPI 2020-01-08 /pmc/articles/PMC7013746/ /pubmed/31936266 http://dx.doi.org/10.3390/ijms21020391 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Baer, Patrick C. Koch, Benjamin Freitag, Janina Schubert, Ralf Geiger, Helmut No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro |
title | No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro |
title_full | No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro |
title_fullStr | No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro |
title_full_unstemmed | No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro |
title_short | No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro |
title_sort | no cytotoxic and inflammatory effects of empagliflozin and dapagliflozin on primary renal proximal tubular epithelial cells under diabetic conditions in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013746/ https://www.ncbi.nlm.nih.gov/pubmed/31936266 http://dx.doi.org/10.3390/ijms21020391 |
work_keys_str_mv | AT baerpatrickc nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro AT kochbenjamin nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro AT freitagjanina nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro AT schubertralf nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro AT geigerhelmut nocytotoxicandinflammatoryeffectsofempagliflozinanddapagliflozinonprimaryrenalproximaltubularepithelialcellsunderdiabeticconditionsinvitro |